-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Contrast: Arcellx (NASDAQ:ACLX) Versus Freeline Therapeutics (NASDAQ:FRLN)
Head-To-Head Contrast: Arcellx (NASDAQ:ACLX) Versus Freeline Therapeutics (NASDAQ:FRLN)
Arcellx (NASDAQ:ACLX – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Insider and Institutional Ownership
92.3% of Arcellx shares are held by institutional investors. Comparatively, 58.5% of Freeline Therapeutics shares are held by institutional investors. 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Get Arcellx alerts:Analyst Ratings
This is a breakdown of current ratings and target prices for Arcellx and Freeline Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Freeline Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
Profitability
This table compares Arcellx and Freeline Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Freeline Therapeutics | N/A | -101.38% | -67.17% |
Valuation & Earnings
This table compares Arcellx and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.72 |
Freeline Therapeutics | N/A | N/A | -$140.39 million | ($2.12) | -0.27 |
Arcellx is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Arcellx beats Freeline Therapeutics on 6 of the 10 factors compared between the two stocks.
About Arcellx
(Get Rating)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
About Freeline Therapeutics
(Get Rating)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx (NASDAQ:ACLX – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
納斯達克:ACLX-GET評級)和Freeline治療公司(納斯達克:FRLN-GET評級)都是小盤醫療公司,但哪隻股票更好?我們將根據兩家公司的分析師建議、機構持股、估值、盈利能力、股息、風險和收益的強弱對它們進行比較。
Insider and Institutional Ownership
內部人與機構持股
92.3% of Arcellx shares are held by institutional investors. Comparatively, 58.5% of Freeline Therapeutics shares are held by institutional investors. 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Arcellx 92.3%的股份由機構投資者持有。相比之下,Freeline治療公司58.5%的股份由機構投資者持有。Freeline治療公司1.9%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一家公司有望實現長期增長。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and target prices for Arcellx and Freeline Therapeutics, as provided by MarketBeat.
這是MarketBeat提供的Arcell和Freeline治療公司的當前評級和目標價格的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Freeline Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
阿爾塞克斯 | 0 | 0 | 8 | 0 | 3.00 |
Freeline治療公司 | 0 | 1 | 4 | 0 | 2.80 |
Profitability
盈利能力
This table compares Arcellx and Freeline Therapeutics' net margins, return on equity and return on assets.
此表比較了Arcell和Freeline治療公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Freeline Therapeutics | N/A | -101.38% | -67.17% |
淨利潤率 | 股本回報率 | 資產回報率 | |
阿爾塞克斯 | 不適用 | -68.99% | -42.26% |
Freeline治療公司 | 不適用 | -101.38% | -67.17% |
Valuation & Earnings
估值與收益
This table compares Arcellx and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.
此表比較了Arcell和Freeline治療公司的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.72 |
Freeline Therapeutics | N/A | N/A | -$140.39 million | ($2.12) | -0.27 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
阿爾塞克斯 | 不適用 | 不適用 | -6,497萬元 | ($44.41) | -0.72 |
Freeline治療公司 | 不適用 | 不適用 | -1.4039億美元 | ($2.12) | -0.27 |
Arcellx is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcell的市盈率低於Freeline治療公司,這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Arcellx beats Freeline Therapeutics on 6 of the 10 factors compared between the two stocks.
Arcell在兩隻股票之間的10個因素中有6個擊敗了Freeline治療公司。
About Arcellx
關於Arcellx
(Get Rating)
(獲取評級)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Arcell,Inc.是一家臨牀階段的生物技術公司,致力於為癌症和其他不治之症患者開發各種免疫療法。該公司主要的ddCAR候選產品是CART-ddBCMA,這是一種治療復發或難治性(r/r)多發性骨髓瘤(MM)患者的第一階段臨牀試驗。該公司還在開發ACLX-001,這是一種由ARC-T細胞和針對BCMA的雙價SPARX蛋白組成的免疫治療組合,用於治療r/r MM;ACLX-002和ACLX-003用於治療r/r急性髓系白血病(AML)和骨髓增生異常綜合徵(MDS);以及其他AML/MDS候選產品,以及實體腫瘤計劃。該公司前身為Encarta治療公司,並於2016年1月更名為Arcell,Inc.。Arcell,Inc.成立於2014年,總部位於馬裏蘭州蓋瑟斯堡。
About Freeline Therapeutics
關於Freeline治療公司
(Get Rating)
(獲取評級)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Freeline治療控股公司是一家臨牀階段的生物技術公司,為患有遺傳性全身性衰弱疾病的患者開發變革性腺相關病毒(AAV)載體介導的基因療法。該公司的先進候選產品是verbrinacogene setparvovec(FLT180a),這是一種用於治療血友病B的成年男性候選基因治療產品,目前正處於1/2階段臨牀試驗。該公司的產品還包括治療Fabry病處於1/2階段臨牀試驗的FLT190,以及治療1型高謝病的候選肝臟基因治療產品FLT201。此外,它還在系統基因治療的各種適應症上制定了研究計劃。該公司成立於2015年,總部設在英國史蒂夫尼奇。
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcell Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收Arcell和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧